Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results

Vistagen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02, Zacks reports. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%.

Vistagen Therapeutics Trading Up 4.0 %

VTGN traded up $0.11 on Thursday, hitting $2.85. 191,949 shares of the company were exchanged, compared to its average volume of 220,406. The firm has a 50-day moving average price of $2.79 and a two-hundred day moving average price of $3.00. Vistagen Therapeutics has a twelve month low of $2.22 and a twelve month high of $5.74. The company has a market cap of $79.34 million, a price-to-earnings ratio of -2.30 and a beta of 0.77.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.